[A phase Ⅲ clinical study to evaluate the efficacy and safety profile of antaitasvir phosphate combined with yiqibuvir in the treatment of adults with chronic hepatitis C].
Year: 2025
Type: article
Abstract: The combination of antaitasvir phosphate 100 mg combined with yiqibuvir 600 mg demonstrates significant efficacy and a good safety profile in patients with CHC with genotypes 1, 2, 3, and 6, without cirrhosis or with compensated cirrhosis, who have received interferon-based treatment or have received initial treatment.
Source: PubMed
Institutions: Beijing Tsinghua Chang Gung Hospital, Tsinghua University, Henan Provincial People's Hospital, Chongqing University, Luoyang Central Hospital Affiliated to Zhengzhou University, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Yanbian University Hospital, Jilin University, First Hospital of Jilin University, West China Hospital of Sichuan University, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, First Affiliated Hospital of Xinxiang Medical University, Guizhou Provincial People's Hospital, First Affiliated Hospital of Xi'an Jiaotong University, Zhengzhou People's Hospital, First Affiliated Hospital of Nanchang University, First People's Hospital of Yunnan Province, Anhui Medical University, Second Affiliated Hospital of Anhui Medical University, Nanjing Second Hospital, Renmin Hospital of Wuhan University, First Hospital of Lanzhou University
Language: English
Topic: Hepatitis C virus research
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4412473586